Table 3.

Ide-cel versus cilta-cel based on their efficacy and adverse events in MM treatment based on KarMMa trial and CARTITUDE- 1.

CAR T cell	Study	Pts	ORR	≥CR	≥VGPR	MRD negativity at 10-5*	PFS	OS	DoR	Any grade CRS	Grade≥3 CRS	Any grade ICANS	Grade ≥3 ICANS
Ide-cel	KarMMa trial (25, 26, 63)	127	73%	33.1%	57.9%	26%	8.6mo.	24.8 mo.	10.9mo.	84%	5%	18%	3%
Cilta cel	CARTITUDE- 1 (43)	97	97.9%	80.4%	94.8%	91.8%	12mo. in 66%	12 mo. in 81%	21.8 mo.	94.8%	4.1%	20.6%	10.3%

*Among MDR evaluable patients; mo, months; pts, number of treated patients.